|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Blood, 1 December 2005, Vol. 106, No. 12, pp. 3958-3961. Prepublished online as a Blood First Edition Paper on August 4, 2005; DOI 10.1182/blood-2005-02-0583.
NEOPLASIA Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylateFrom the Molecular Pathology Group at the Heinrich-Pette-Institut and the Department of Medicine II, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; and the Developmental Biology Program, Sloan-Kettering Institute, New York, NY.
Multiple genetic alterations are required to induce acute myelogenous leukemia (AML). Mutations in the extracellular domain of the KIT receptor are almost exclusively found in patients with AML carrying translocations or inversions affecting members of the core binding factor (CBF) gene family and correlate with a high risk of relapse. We demonstrate that these complex insertion and deletion mutations lead to constitutive activation of the KIT receptor, which induces factor-independent growth of interleukin-3 (IL-3)–dependent cells. Mutation of the evolutionary conserved amino acid D419 within the extracellular domain was sufficient to constitutively activate the KIT receptor, although high expression levels were required. Dose-dependent growth inhibition and apoptosis were observed using either the protein tyrosine kinase inhibitor imatinib mesylate (STI571, Gleevec) or by blocking the phosphoinositide-3-kinase (PI3K)–AKT pathway. Our data show that the addition of kinase inhibitors to conventional chemotherapy might be a new therapeutic option for CBF-AML expressing mutant KIT.
Acute myelogenous leukemia (AML) is a complex disease that is classified by histochemical, cytochemical, and genetic markers. Genetic alterations affecting members of the core binding factor (CBF), a heterodimeric transcription factor, are some of the most common events in AML and define a large group commonly designated CBF-AML,1 which includes patients with either t(8;21) or inv(16). Evidence from experimental studies supports the hypothesis that these fusion proteins impair myeloid differentiation and/or expand a hematopoietic stem/progenitor cell pool, but are insufficient to cause leukemia.2-6 Secondary genetic alterations, such as mutations in receptor tyrosine kinases (RTKs), are thus required for induction of an overt AML. Although the KIT receptor is expressed on the majority of AML blasts, mutations in the KIT gene are exclusively associated with CBF-AML.7-11 In addition to mutations affecting D816 within the KIT tyrosine kinase domain 2 (TK2), complex insertion/deletion mutations in exon 8 affecting the extracellular (EC) domain are also observed in CBF-AML, with an especially high prevalence (26%) in inv(16) patients, and correlate with a higher risk of relapse.8,9 In addition to EC mutations, a mutation in the transmembrane (TM) domain (V530I) has also been described in CBF-AML.9,11 Previous studies have shown that the KIT D816V mutation induces growth factor–independent growth of myeloid and mast cells and is insensitive to the RTK inhibitor imatinib mesylate (STI571, Gleevec [manufactured by Novartis, Basel, Switzerland]).12-14 The purpose of this study was to test the functional activity of the EC and TM KIT mutations associated with CBF-AML, to determine their sensitivity to imatinib, and to delineate the activated signaling pathways.
Site-directed mutagenesis was used to create KIT mutants from either murine or human KIT cDNAs, as indicated in Table 1. KIT mutants were cloned into the SF91 retroviral vector coexpressing the yellow fluorescence protein (YFP), and were used to infect FDC-P1 cells in the presence of interleukin-3 (IL-3).3 Transduced cells were detected by fluorescence-activated cell sorting (FACS) and directly sorted into 96-well plates with or without IL-3 to calculate the incidence of factor-independent growth. KIT mutations in the factor-independent cells were verified by sequencing. To monitor proliferation rates, cells (104/well) were pulsed for 8 hours with methyl-3H thymidine (18.5 MBq [0.5 µCi]/well; specific activity, 1.85 TBq [50 Ci]/mmol) and incorporation levels were determined. Early and late apoptosis was evaluated using the apoptosis detection kit (R&D Systems, Minneapolis, MN).
To analyze the oncogenic potential of KIT mutations that have been identified in CBF-AML, a series of KIT mutants were tested for their ability to stimulate proliferation and inhibit apoptosis of myeloid cells. First, 2 KIT mutants were generated that have been cloned from patients with AML,9 one with a V530I substitution in the TM domain and a second with a complex deletion/insertion mutation affecting the EC domain (T417  , Y418, D419, InsV; designated "exon 8"). As all EC in-frame deletion plus insertion mutations observed in AML lead to the loss of the evolutionary highly conserved amino acid D419,9 we also created a mutant (D419A), in which the acidic Asp is replaced with the neutral hydrophobic Ala. This mutant directly tests if loss of D419 is the critical mutation in these mutants. As a positive control for growth stimulation, we used the TK2 mutants hD816V and mD814V and the juxtamembrane (JX) mutant mV558D, identified in mastocytosis and gastrointestinal-stroma tumors (GIST).16,17 These mutants also served as negative (mD814V/hD816V) and positive (mV558D) controls for the response to imatinib.18 Expression of each of the KIT mutants in IL-3–dependent FDC-P1 cells led to factor-independent growth under stringent conditions, but with different efficiencies (Table 1). Whereas the TK2 and JX mutants gave rise to factor-independent cells at a frequency between 10-2 and 10-3, the frequency was 2 to 3 orders of magnitude lower for EC and TM mutants. Importantly, no spontaneous factor-independent growth was observed in control infected FDC-P1 cells expressing YFP alone or wild-type KIT, supporting the conclusion that expression of the EC and TM KIT mutants was responsible for the factor-independent growth. The low frequency of obtaining factor-independent growth with these mutants relative to the JX and TK2 mutations may reflect the necessity of high KIT expression levels. This hypothesis is supported by the fact that the transcription levels of the vectors (as measured by YFP expression) was 3- to 6-fold higher in IL-3–independent cultures expressing EC and TM mutants, as compared with the other mutants (Figure 1A). This was further documented by examination of KIT protein levels by Western blot analysis, which correlated well with YFP expression levels (Figure 1B), although a direct comparison is complicated by potential differences in receptor turnover rates. Notably, all cultures proliferated at comparable rates and no significant differences in proliferation rates were observed if IL-3 was added to the cultures, demonstrating optimal cell growth in the selected cultures (data not shown). To determine if the EC and TM mutants are sensitive to RTK inhibitors, we tested the effect of imatinib on the factor-independent growth of FDC-P1 cells expressing the KIT mutants in proliferation assays. Under pharmacologic doses of imatinib, FDC-P1 cultures expressing EC and TM mutants showed a drastic reduction in proliferation (Figure 1C), which could be rescued by addition of IL-3 (data not shown). The inhibitory concentration (IC50) dose required for these mutants was lower (0.1 µM) than that for wild-type KIT stimulated with stem cell factor (SCF) (0.5 µM), but was similar to that required for V558D mutants, commonly observed in imatinib-responsive GIST patients.18 The inhibition of V530I is consistent with recent results with another TM mutant (F522C) identified in mastocytosis.19 Inhibition of EC and TM mutant KIT activity not only abrogated proliferation, but induced high frequencies of apoptosis, as detected by annexin-V staining (Figure 1D). To confirm if growth inhibition and apoptosis was directly mediated by inhibiting KIT mutant activity, phosphorylation status of the different KIT mutants was evaluated in the absence and presence of different imatinib concentrations (Figure 1E). Consistent with the hypothesis that the KIT mutations lead to activation of the receptor, KIT phosphorylation was observed in all cultures expressing KIT mutants. At pharmacologic doses of 1 µM imatinib, inhibition of both TM and JX, but not TK2 mutant, phosphorylation was observed, consistent with their response to imatinib in proliferation and apoptosis assays. Somewhat surprisingly, only slightly lower phosphorylation levels of the EC mutant were observed after imatinib treatment, despite its striking sensitivity to the drug in biologic assays. Examination of KIT downstream signaling pathways20 clearly demonstrated that the imatinib-mediated inhibition of cell growth and induction of apoptosis correlated with phosphorylation of AKT, mitogen-activated protein kinase (MAPK), and signal transducers and activators of transcription 5 (STAT5), but not STAT3 (Figure 1E). The critical importance of the phosphatidylinositol-3-kinase (PI3K)–AKT pathway was demonstrated with chemical inhibitors for the different pathways (Figure 1F). Strikingly, the PI3K-inhibitor LY294002 reduced proliferation rates of FDC-P1 cells expressing either the EC or JX KIT mutants to levels similar to that observed by directly inhibiting the KIT receptor using imatinib, in contrast to the MAPK inhibitor PD98059, which only partially inhibited proliferation. Indeed, the PI3K inhibitor was alone sufficient to inhibit proliferation of the TK2 KIT mutants, resistant to imatinib. Rapamycin, which inhibits the AKT downstream effector mammalian target of rapamycin (mTOR), only partially inhibited proliferation, underlining the importance of other known downstream effectors of PI3K-AKT. In summary, we show that both the EC (exon 8) and TM mutants, which are found in CBF-AMLs at a high frequency, lead to constitutive activation of KIT. Furthermore, our data demonstrate that disruption of Asp419 is the critical event in EC mutations. Both the low transforming frequency in our assay, as well as the exclusive association with CBF-AMLs, suggest that high KIT expression levels or other secondary cooperating events may be a prerequisite for the transforming properties of EC or TM mutations. Interestingly, a recent study has shown that the fusion protein generated by t(8;21) induces high KIT expression levels in U937 cells.10 The striking responsiveness of both EC and TM KIT mutants to imatinib demonstrates that RTK inhibitors in combination with conventional chemotherapy may be a novel therapeutic approach for the treatment of CBF-AML carrying EC or TM KIT mutations. Although recent studies have evaluated the response of AML to kinase inhibitors with only very limited response,21-23 the KIT status (wild type or mutant) was only evaluated in one of these trials, where no EC or TM mutations were identified.22 Thus our data, together with studies investigating the use of kinase inhibitors in non–small cell lung cancer,24,25 argue for the importance of careful patient selection in clinical studies to evaluate the effectiveness of kinase inhibitors.
We would like to thank Marion Ziegler and Susanne Roscher for excellent technical assistance, Arne Düsedau for FACS support, and other members of the Stocking lab for helpful discussion. We also gratefully acknowledge Paulo De Sepulveda and Patrice Dubreuil (Marseille, France) for providing mutants D816V and V558D, and Novartis (Basel, Switzerland) for providing imatinib mesylate.
Submitted March 3, 2005; accepted July 27, 2005.
Prepublished online as Blood First Edition Paper, August 4, 2005; DOI 10.1182/blood-2005-02-0583.
Supported by the Deutsche José Carreras Leukämie Stiftung (C.S., G.S.) and the Deutsche Krebshilfe (J.C., C.S.).
J.C. and S.H. contributed equally to this work.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Carol Stocking, Molecular Pathology, Heinrich-Pette-Institut, PO Box 201 652, D-20206 Hamburg, Germany; e-mail: stocking{at}hpi.uni-hamburg.de.
  CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2005 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
